 Gilead Sciences Inc NASDAQ: GILD ended this week up nearly 20 after reporting its quarterly results that handily topped Street estimates and subsequently winning an upgrade from a Truist analyst. Gilead stock could climb another 15 Robyn Karnauskas now sees upside in the biotech firm to 91 up another 15 from here. 